Latest / Oncology Data Advisor
Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.